This construct combines the well-characterized RGD peptide with GE11, a non-mitogenic peptide ligand for EGFR, allowing for simultaneous targeting of integrins and EGFR, both of which are implicated in pancreatic cancer progression and resistance to therapy. Here, EGFR is linked to familial pancreatic carcinoma.